Archer Materials Reports $11.6M Cash, Advances Qubit Readout and Biochip Accuracy
Archer Materials has made significant strides in quantum computing and biochip development, enhancing qubit functionality and potassium ion testing accuracy. A new partnership with IMEC aims to accelerate biochip commercialization, supported by a robust $11.6 million cash position.
- Enhanced quantum qubit readout via electrical detection of magnetic resonance
- Improved potassium ion testing accuracy meets clinical lab standards
- Partnership with IMEC to develop scalable silicon-based biochips alongside graphene
- Tunnel Magnetoresistance sensors validated for cryogenic temperature operation
- Strong cash reserves of $11.6 million with no debt to fund R&D and commercialization
Quantum Technology Breakthroughs
Archer Materials has reported notable progress in its quantum technology initiatives during the first quarter of fiscal 2026. The company’s CQ project achieved a key milestone by demonstrating electrical detection of magnetic resonance (EDMR) on its carbon qubit film material. This advancement, developed in collaboration with the École Polytechnique Fédérale de Lausanne (EPFL), marks a significant step toward practical qubit readout systems expected in 2026.
Unlike traditional optical methods, Archer’s electrical readout approach promises simpler, more scalable quantum sensors. The integration of EDMR detection circuits directly onto semiconductor chips aligns with industry fabrication standards, potentially reducing system complexity and accelerating commercial quantum device development.
Additionally, Archer advanced its Tunnel Magnetoresistance (TMR) sensor technology to operate effectively at cryogenic temperatures. This capability is crucial for quantum computing and sensing applications in extreme environments such as aerospace, defence, and space exploration.
Biochip Development Accelerates with IMEC Partnership
On the medical diagnostics front, Archer’s Biochip project made significant headway. The company improved potassium ion testing accuracy to meet Clinical Laboratory Improvement Amendments (CLIA) standards, a critical benchmark for clinical readiness. This progress lays the groundwork for a handheld diagnostic prototype slated for 2026, intended for pilot clinical trials targeting patient monitoring.
Crucially, Archer expanded its biochip platform beyond graphene by partnering with Belgium’s Interuniversity Microelectronics Centre (IMEC) to develop silicon-based biochips. Silicon’s established industry use offers a scalable manufacturing pathway, reducing commercialization risks by diversifying the technology base.
The biochip platform’s adaptable design allows for detection of multiple ions beyond potassium, opening potential applications across healthcare, environmental monitoring, and industrial process control. Early testing on other ions has already commenced, leveraging the platform’s flexible sensor architecture.
Financial Position and Outlook
Archer Materials ended the quarter with a strong cash balance of $11.6 million and no debt, providing a solid financial foundation to support ongoing research, development, and commercial activities. Quarterly cash flow reflected continued investment in R&D and operational costs, consistent with the company’s growth trajectory.
Executive Chair Greg English highlighted the company’s momentum, emphasizing the strategic partnership with IMEC as a catalyst for scaling biochip manufacturing and the promising advances in quantum sensing technologies. Archer’s roadmap anticipates further milestones in 2026, including prototype completion and clinical trial commencement.
Bottom Line?
With robust funding and key technological milestones achieved, Archer Materials is poised to translate quantum and biochip innovations into commercial realities in the coming year.
Questions in the middle?
- How will Archer’s silicon-based biochip performance compare to graphene in clinical settings?
- What are the timelines and potential hurdles for the upcoming pilot clinical trials?
- Can Archer’s quantum sensing technologies secure partnerships in aerospace or defence sectors?
